Aestas Pharma

Aestas Pharma is a pre-clinical stage biopharmaceutical company. It develops diagnostic imaging and therapeutic agents to enable the early detection and reversal of Alzheimer’s diseases (AD) and Parkinson’s disease (PD). It offers AP-251, a diagnostic biomarker candidate targeting a disease specific aberrant Cdk5 complex.